Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.

NCT00235508 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT00235508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00235508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2005
Completion date
April 30, 2006
Enrollment
420 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

generalized anxiety disorder, insomnia